Key result
Cisplatin-based chemotherapy linked to unexpected acute endo-aortic thrombosis resolving with anticoagulation.
Why the study?
Aortic thrombosis without atherosclerosis, dissection, or aneurysms is rare, and cancer-related hypercoagulability is a known risk factor for venous thrombosis but rarely reported for atrial thrombosis in cancer patients.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
Raises caution for aortic thrombosis during cisplatin therapy in gastric cancer; leaves open the need for prospective studies on prevention.
The development of aortic thrombosis without the presence of atheroscrelosis, dissection, or aneurysms is rare. A cancer-related hypercoagulable state is a well-known risk factor for venous thrombosis, however, atrial thrombosis has rarely been reported in cancer patients. Cisplatin-based chemotherapy is known to cause various side-effects. Detecting aortic thrombosis is important because it is a fatal condition. We herein present the first reported case of endo-aortic thrombosis occurring during cisplatin-based chemotherapy for gastric cancer.
No takes yet. Share an insight, caveat, or question.
Ito et al. (2013) conducted a case report in Gastric cancer (n=1). Cisplatin and S-1 chemotherapy was evaluated on Development of endo-aortic thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: